Evidence map›Paper›PMID 40039977›Full record

ArticleAnnual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference2024

Predicting Nonalcoholic Fatty Liver Disease in Obese Populations with 3D Body Scans.

Yijiang Zheng, Zhuoxin Long, Ruting Cheng, Boyuan Feng, Khashayar Vaziri, Xiaoke Zhang, James K Hahn

Abstract read
In one paragraph

Article in Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yijiang Zheng
Zhuoxin Long
Ruting Cheng
Boyuan Feng
Khashayar Vaziri
Xiaoke Zhang
James K Hahn

Funding

Advancing 3D optical body surface scan technology to assess physiological and psychological effects in highly obese populationR01DK129809 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI HAHN, JAMES K · 2021 to 2024
$2.2M
NIDDK NIH HHS R01 DK129809
6 · The paper itself

Abstract

Nonalcoholic Fatty Liver Disease (NAFDL), characterized by the accumulation of fat in the liver, is considered a significant threat to public health, particularly in conjunction with obesity and the presence of Nonalcoholic Steatohepatitis (NASH). Traditional clinical methods for evaluating NAFDL, such as liver biopsy and MRI, are either invasive or costly. The utilization of 3D body scans offers a noninvasive and efficient approach to capture precise body shape information rapidly. This study explores the correlation between NAFLD and body shape information in the obese population applying various machine learning models over diverse 3D shape features. The results of the experiments indicate that NAFDL exhibits a stronger association with features containing more intricate shape details. Point cloud features extracted from the 3D trunk region outperform other shape descriptors, such as girth measurements, achieving the highest accuracy at 72% and the F1 score exceeding 0.8 in the classification. These findings suggest that 3D body scans present a promising and cost-effective alternative for the diagnosis of hepatic steatosis. 3D body scans could be valuable in identifying NAFDL and NASH at an early stage, offering a more accessible option for individuals at risk for fatty liver.

Indexed as

Imaging, Three-DimensionalNon-alcoholic Fatty Liver DiseaseObesityAdultFemaleHumansMachine LearningMaleMiddle Aged

Identifiers

PMID40039977
PMCPMC11884670

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.